Biomarkers in osteoarthritis

Current Opinion in Rheumatology

Volumn 15, Issue 5, 2003, Pages 641-646

  Garnero, Patrick ^a,b   Delmas, Pierre D ^a  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Cartilage; Cartilage oligomeric matrix protein; Osteoarthritis; Synovium; Type II collagen

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 2;

BONE TURNOVER; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DISEASE COURSE; HUMAN; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE PROGRESSION; HUMANS; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 0041828558     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200309000-00020     Document Type: Review

References (40)

1. Dove A: Biomarkers database may yield blockbuster drug. Nat Med 2002, 8:1049-1050.
2. Garnero P, Rousseau JC, Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000, 43:953-968.
3. Otterness IG, Swindell AC: Criteria for selection and application of molecular markers for clinical studies of osteoarthritis. Osteoarthritis Cartilage 2003, 11:153-158. This brief review provides useful information including a statistical consideration to compare the clinical performances of different biologic markers for OA.
4. Kraus VB, Huebner JL, Finck C, et al.: Urea as a passive transport marker for arthritis studies. Arthritis Rheum 2002, 46:420-427.
5. Garnero P, Delmas PD: In: Investigation of Bone: Bone Turnover in Rheumatology, edn 3. Edited by Hochberg MC, Silman AJ, Smolen JS, et al., eds. London, UK: Harcourt Health Sciences; in press.
6. Christgau S, Garnero P, Fledelius C, et al.: Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
7. Andersson M, Jonsson N, Petersson IF, et al.: Diurnal variation of serum COMP in individuals with knee pain and osteoarthritis [Abstract]. Ann Rheum Dis 2002, 61:47.
8. Blesh A, Bosserhoff AK, Apfel et al.: Cloning of a novel malignant melanoma-derived growth-regulatory protein. MIA. Cancer Res 1994, 54:5695-5701.
9. Schmidt-Rohfing B, Schneider U, Thomsen M, et al.: Correlation of a novel matrix protein with the degree of cartilage degradation. Rheumatol Int 2002, 22:165-169.
10. Saito S, Kondo S, Mishima S, et al.: Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br 2002, 84:1066-1069.
11. Aigner T, Zhu Y, Chansky HH, et al.: Re-expression of type II A procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999, 42:1443-1450.
12. Garnero P, Ayral X, Rousseau J-C, et al.: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002, 46:2613-2624. This is a 1 -year longitudinal study of patients with knee OA that evaluates disease progression with both radiographs and arthroscopy, and indicates for the first time that the combined use of markers reflecting type II synthesis and degradation provide additional power to predict progression in OA.
13. Nelson F, Dahlberg L, Laverty S, et al.: Evidence of altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998, 102:2115-2125.
14. Poole R. Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? Arthritis Rheum 2002, 46:2549-2552. This is a brief review of the pathophysiologic processes of OA and their implications for the development of valuable biologic markers for OA.
15. DiCesare PE, Fang C, Leslie MP, et al.: Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts. J Orthop Res 2000, 18:713-720.
16. Vilim V, Vytasek R, Olejarova M, et al.: Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001, 9:612-618.
17. Chu Q, Lopez M, Hayashi K, et al.: Elevation of collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage 2002, 10:662-669.
18. Henrotin Y, Deberg M, Christgau S, et al.: Type II collagen derived fragment (COLL 2-1) is a new marker predictive of osteoarthritis progression. Osteoporos Int 2002, 13(suppl 3):S17.
19. Pelletier J-P, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease. Arthritis Rheum 2001, 44:1237-1247.
20. Ayral X, Pickering EH, Woodworth TG, et al.: Synovitis predicts the arthroscopic progression of medial tibiofemoral knee osteoarthritis. Arthritis Rheum 2001; 44(S9):S101.
21. Gineyts E, Garnero P, Delmas PD: Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology 2001, 40:315-323.
22. Garnero P, Piperno M, Gineyts E, et al.: Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001, 60:619-626.
23. Jordan JM, Luta G, Stabler T, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 2003, 48:675-681. This is a comprehensive analysis of the effects of ethnicity, gender, age, body weight, and joint damage involvement on serum COMP levels with an elegant discussion providing new hypotheses on the pathophysiology of OA.
24. Mouritzen U, Christgau S, Lehman H-J, et al.: Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003, 62:332-336.
25. Nakayama Y, Narita T, Mori A, et al.: The effects of age and sex on chondroïtine sulfates in normal synovial fluid. Arthritis Rheum 2002, 46:2105-2108.
26. Dragomir AD, Kraus VB, Renner JB, et al.: Serum oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 2002, 10:687-691.
27. Sowers M, Jannausch M, Stein E, et al.: C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002, 10:595-601.
28. Bettica P, Cline G, Hart DJ, et al.: Evidence for increased bone resorption in patients with progressive knee osteoarthritis. Longitudinal results from the Chingford study. Arthritis Rheum 2002, 46:3178-3184. This long-term prospective study provides evidence that increased bone resorption as detected by systemic biologic markers is a risk factor for OA progression. These findings also provide a rationale for the investigation of therapeutic modulation of bone turnover to reduce progression.
29. Vilim V, Olejarova M, Machacek S, et al.: Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002, 10:707-713.
30. Sugiyama S, Itokazu M, Suzuki Y, et al.: Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003, 62:27-32. This is a 4-year longitudinal study of a large and well-characterized population of patients with very early knee OA, suggesting that progression of joint space loss (as assessed by state-of-the-art radiographs) is associated with increased baseline synovial fluid levels of type II collagen synthesis.
31. Cerejo R, Poole AR, Ionescu M, et al.: The association between cartilage collagenase activity measured in serum and progression of knee osteoarthritis in patients with and without evidence of generalized disease. Arthritis Rheum 2002, 46(suppl 9):S144.
32. Garnero P, Conrozier T, Christgau S, et al.: Urinary type II collagen C-telopeptide levels are increased in patients with a rapidly destructive hip osteoarthritis. Ann Rheum Dis In press.
33. Masuhara K, Nakai T, Yamaguchi K, et al.: Significant increases in serum and plasma concentrations of matrix metalloproteinase 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002, 10:2625-2631.
34. Garnero P, Gineyts E, Christgau S, et al.: Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:21-30.
35. Garnero P, Landewe R, Maarten B, et al.: Association of baseline levels of markers of bone and cartilage degradation are associated with long term progression of joint damage in patients with early rheumatoid arthritis: the Cobra study. Arthritis Rheum 2002, 46:2847-2856. This study shows that among different parameters including disease activity indices, C-reactive protein, and baseline radiologic joint damage, systemic biological markers of bone and cartilage degradation are the most powerful predictors of 5-year progression in patients with early rheumatoid arthritis.
36. Garnero P, Christgau S, Delmas PD: The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001, 28:461-464.
37. Lehmann HJ, Mouritzen U, Christgau S, et al.: Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002, 61:530-533. This paper reports a dose-dependent decrease of a marker of type II collagen destruction in two placebo-controlled studies of alendronate and ibandronate in postmenopausal women. These findings suggest a potential role of bisphosphonates as a chondroprotective agent for OA.
38. Delmas PD, Gineyts E, Mo J, et al.: Effects of ibuprofen on type II collagen C-telopeptide (u-CTX-II) levels, a marker of cartilage degradation, in patients with osteoarthritis (OA) of the knee. Arthritis Rheum 2001, 44(suppl 9):S139.
39. Leff RL, Elias I, Ionescu A, et al.: Molecular changes in human osteoarthritis cartilage after 8 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 2003, 30:544-549.
40. Garnero P, Landewe R, Boers M, et al.: Short-term reduction in urinary CTX-II, a marker of cartilage degradation, predicts long-term rediological progression in patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic therapy (DMARD). Arthritis Rheum 2002, 46(suppl 9):S376.